

CLEAN VERSION OF EACH REPLACEMENT PARAGRAPH/SECTION/CLAIM AND
INSTRUCTIONS FOR ENTRY

IN THE SPECIFICATION:

A1
As a result of these procedures, the disease specific markers namely proapo-A-I-protein having a molecular weight of about 1301.61 daltons and a sequence of SEQ ID NO: 1, apolipoprotein A-I precursor having a molecular weight of about 1188.58 daltons and a sequence of SEQ ID NO: 2, prealbumin/transthyrin pre-albumin amyloidosis type I having a molecular weight of about 1366.7595 and a sequence of SEQ ID NO: 3 and a molecular weight of about 2450 and a sequence of SEQ ID NO: 4, fibrinogen gamma chain having a molecular weight of about 1683 daltons and a sequence of SEQ ID NO: 5, related to insulin resistance was found.

IN THE CLAIMS:

A2
1. A biopolymer marker selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 or at least one analyte thereof useful in indicating at least one particular disease state.

A3
2. The biopolymer marker of claim 1 wherein said disease state is predictive of insulin resistance.

A4
18. A kit for diagnosing, determining risk-assessment, and identifying therapeutic avenues related to a disease state comprising:
at least one biochemical material which is capable of specifically binding with a biomolecule